Lead Product(s) : Lixudebart,GlucoCorticoid,Rituximab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alentis Announces Positive Results for Lixudebart in ANCA-RPGN Liver Fibrosis
Details : ALE.F02 (lixudebart) is a claudin 1 inhibitor antibody, which is currently being evaluated for antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.
Product Name : ALE.F02
Product Type : Antibody
Upfront Cash : Inapplicable
January 09, 2025
Lead Product(s) : Lixudebart,GlucoCorticoid,Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MoonLake Announces Positive FDA and EMA Feedback for Ph 3 of Sonelokimab in Arthritis
Details : M1095 (sonelokimab) is an investigational 40kDa humanized nanobody. It is currently being assessed in lead indications of pateints suffering from psoriatic arthritis.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
October 06, 2024
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for psori...
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
July 25, 2023
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : SVB Securities
Deal Size : $250.0 million
Deal Type : Public Offering
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
Details : MoonLake intends to use the proceeds to fund the ongoing advancement of M1095, a novel investigational Nanobody® for the treatment of inflammatory disease. Sonelokimab inhibits IL-17A and IL-17F by inhibiting the IL-17A/A, IL-17A/F, and IL-17F/F dimers ...
Product Name : M1095
Product Type : Antibody
Upfront Cash : Undisclosed
June 26, 2023
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : SVB Securities
Deal Size : $250.0 million
Deal Type : Public Offering
Lead Product(s) : Lixudebart,Glucocorticoid,Rituximab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ALE.F02 (Lixudebart Rituximab GlucoCorticoid) is a claudin 1 inhibitor antibody drug candidate, which is currently being evaluated for the treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rapidly progressive glomerulonephritis.
Product Name : ALE.F02
Product Type : Antibody
Upfront Cash : Inapplicable
May 12, 2023
Lead Product(s) : Lixudebart,Glucocorticoid,Rituximab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Apraglutide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Asahi Kasei Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
VectivBio and Asahi Kasei Pharma Announce the Start of a Phase 1 Study of Apraglutide in Japan
Details : Apraglutide is a novel long-acting glucagon-like peptide-2 analog designed for to increase fluid and nutrient absorption by the remnant intestine of patients who have short bowel syndrome with intestinal insufficiency or intestinal failure.
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Inapplicable
March 13, 2023
Lead Product(s) : Apraglutide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Asahi Kasei Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to develop an autoinjector for clinical and potential subsequent commercial supply of MoonLake’s Nanobody® M1095 (sonelokimab) by using SHL Medical's market-proven Molly® modular platform technology.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Undisclosed
March 05, 2023
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : MoonLake Immunotherapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MoonLake plans to execute on its development program to unlock the potential of M1095 (Sonelokimab), the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
December 14, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olamkicept
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : I-Mab Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Ferring Announces New Collaboration for Development of Olamkicept
Details : This new collaboration enables Ferring to invest in the development of olamkicept globally and provides an option for I-Mab to collaborate with Ferring in the future development of olamkicept at a pre-defined development milestone.
Product Name : TJ-301
Product Type : Protein
Upfront Cash : Undisclosed
September 06, 2022
Lead Product(s) : Olamkicept
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : I-Mab Biopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Apraglutide
Therapeutic Area : Immunology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : FE203799 (apraglutide) is a next-generation, synthetic GLP-2 analog rationally designed with the potential to offer an improved safety and efficacy profile relative to other agents in its class and less frequent dosing.
Product Name : FE203799
Product Type : Peptide
Upfront Cash : Inapplicable
February 06, 2022
Lead Product(s) : Apraglutide
Therapeutic Area : Immunology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable